Figure 9.

Plasma Cer16:0 and GlcCer16:0 Are Modifiable Risk Biomarkers

(A) A schematic representation of the randomized controlled trial design. (B) A heat map showing the significant differential metabolites between day 0 and week 8. Box plots represent changes in GlcCer16:0 (C,D) and Cer16:0 (E,F) body mass index–normalized concentrations in patients who were randomized to a low-calorie diet or liraglutide treatment (1.2 mg/day) for 52 weeks, following 8 weeks (baseline) of low-calorie diet–induced weight loss. Box plots represent median (interquartile range). Abbreviations as in Figure 8.